Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. (2026). Swiss Medical Weekly, 156(1), 4711. https://doi.org/10.57187/4711